Uroplasty CEO resigns
This article was originally published in Clinica
Executive Summary
David Kaysen has resigned as president and CEO of Uroplasty, a firm specializing in the treatment of urinary incontinence and other pelvic disorders, after seven years at the helm. The company has appointed independent director and former Baxter International veteran Robert Kill interim CEO while its board searches for a permanent replacement. It is unclear why Mr Kaysen decided to leave the Minnetonka, Minnesota company, but it might be down to a mixed performance in fiscal year 2013. Uroplasty is expecting to report fourth-quarter and full-year revenues of $5.5 million (down 2% year-on-year) and $22.4 million (up 9% year-on-year), respectively. However, sales of its flagship Urgent PC device seem healthy; they are expected to be $2.6 million in Q4 (+13%) and $10.5 million for the full fiscal year (+35%). Full results will be available in late May.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.